Physician profile
Hannah E Thomas
NPI 1902276330
$790.87
in general payments reported to CMS, 2019-2025
12 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.59 · 2023: $163 · 2024: $164 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.67 | 2023-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $124.99 | 2025 | Zoryve |
| Amgen INC. | $121.84 | 2023-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $114.80 | 2024 | Airsupra |
| Baxter Healthcare | $88.71 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Genentech USA, INC. | $56.59 | 2021 | |
| Pfizer INC. | $38.91 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $32.03 | 2025 | Rexulti |
| Lilly USA, LLC | $29.35 | 2024-2025 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.43 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $17.85 | 2023 | Quviviq |
| Abbvie INC. | $15.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.